Changes in Beneficial Ownership · 4
Roivant Sciences Ltd.
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1789772501.xml
Filing details
- Report period
- 2026-09-16
- Issuer
- Roivant Sciences Ltd.
- Issuer CIK
- 0001635088
- Trading symbol
- ROIV
Reporting owner 1
- Name
- MOMTAZEE JAMES C
- Reporting owner CIK
- 0001209181
- Relationship
- Director
- Address
- C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM, X0, SW1H 0DB
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares | 2026-09-16 | A · Form 4 | 5,054[F1] | A | 0[F1] | 111,959 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 39.57 | 2026-09-16 | A · Form 4 | 10,531 | A | 0 | [F2] | 2036-09-15 | Common Shares | 10,531 | 10,531 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.↩ 1↩ 2
- F2
- Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.↩ 1
Signature 1
- Signed
- By: /s/ Sam Kaplan, as Attorney-in-Fact for James C. Momtazee
- Date
- 2026-09-18
Company context
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.